SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Cardlytics, Inc. – ‘8-K’ for 6/2/20

On:  Tuesday, 6/2/20, at 4:19pm ET   ·   For:  6/2/20   ·   Accession #:  1666071-20-161   ·   File #:  1-38386

Previous ‘8-K’:  ‘8-K’ on / for 5/11/20   ·   Next:  ‘8-K’ on 7/29/20 for 7/28/20   ·   Latest:  ‘8-K’ on / for 4/9/24

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 6/02/20  Cardlytics, Inc.                  8-K:5       6/02/20   12:282K

Current Report   —   Form 8-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     34K 
 7: R1          Document and Entity Information                     HTML     49K 
 9: XML         IDEA XML File -- Filing Summary                      XML     12K 
12: XML         XBRL Instance -- cdlxform8-k2020annuals_htm          XML     15K 
11: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
 3: EX-101.CAL  XBRL Calculations -- cdlx-20200602_cal               XML      7K 
 4: EX-101.DEF  XBRL Definitions -- cdlx-20200602_def                XML     38K 
 5: EX-101.LAB  XBRL Labels -- cdlx-20200602_lab                     XML     79K 
 6: EX-101.PRE  XBRL Presentations -- cdlx-20200602_pre              XML     42K 
 2: EX-101.SCH  XBRL Schema -- cdlx-20200602                         XSD     16K 
10: JSON        XBRL Instance as JSON Data -- MetaLinks               14±    21K 
 8: ZIP         XBRL Zipped Folder -- 0001666071-20-000161-xbrl      Zip     35K

‘8-K’   —   Current Report

This is an HTML Document rendered as filed.  [ Alternative Formats ]

 iX:   C:   C:   C: 
  Document  
 i false i 0001666071 0001666071 2020-06-02 2020-06-02


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 
FORM  i 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):  i June 2, 2020
 
 
cardlyticsa01.jpg
 i CARDLYTICS, INC.
(Exact Name of Registrant as Specified in its Charter)
 
 i Delaware
 i 001-38386
 i 26-3039436
(State or other jurisdiction of
incorporation or organization)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
 i 675 Ponce de Leon Avenue NE, Suite 6000
 i Atlanta
 i Georgia
 i 30308
(Address of principal executive offices, including zip code)
 
 i (888)
 i 798-5802
 
(Registrant's telephone, including area code)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
 i ☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 i ☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 i ☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 i ☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:
Title of each class
Trading symbol
Name of each exchange on which registered
 i Common Stock
 i CDLX
 i The Nasdaq Stock Market LLC
 Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
 i ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   i ☐





 
Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 2, 2020, Cardlytics, Inc. (the “Company”) held its 2020 annual meeting of stockholders (the “Annual Meeting”). The stockholders considered two proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 20, 2020. Of the 26,956,011 shares outstanding as of the record date, April 6, 2020, 22,848,038 shares or 84.76% of the shares outstanding as of the record date, were present or represented by proxy at the Annual Meeting. Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting.

Proposal No. 1: Election of three nominees to serve as directors until the 2023 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows:
Name
    
Votes For
    
Votes Withheld
Lynne M. Laube
 
16,209,184

 
2,595,571

John Klinck
 
15,503,904

 
3,300,851

Tony Weisman
 
9,975,868

 
8,828,887


Broker Non-Votes: 4,043,283.

All nominees were elected.

Proposal No. 2: Ratification of the appointment of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2020. The votes were cast as follows:
 
Votes For
    
Votes Against
    
Abstained
Ratification of appointment of Deloitte & Touche LLP
22,529,296

 
240,652

 
68,131









SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
Cardlytics, Inc.
 
 
 
 
Date:
June 2, 2020
By:
/s/ Andrew Christiansen
 
 
 
Andrew Christiansen
 
 
 
Chief Financial Officer
(Principal Financial and Accounting Officer)


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
12/31/20
Filed on / For Period end:6/2/204,  DEF 14A
4/20/204,  DEF 14A,  DEFA14A
4/6/204
 List all Filings 
↑Top
Filing Submission 0001666071-20-000161   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Tue., Apr. 23, 6:52:40.1pm ET